Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Viral and host factors influence likelihood of response to interferon-based therapy (Table 35) (Table 36)[Sarrazin 2010]
    • Viral Factors
    • Subgenotype 1a has lower barrier to resistance to protease and NS5A inhibitors than subgenotype 1b[Halfon 2011]
    • Presence of NS5A RAVs at baseline in patients with genotype 1a HCV infection lowers SVR rate for elbasvir/grazoprevir, necessitating longer duration therapy and/or addition of ribavirin
    Host Factors

    Action required

    Keywords: Hepatitis C-Treatment

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.